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Translational Relevance: 
Progress in the development of effective cancer treatments is limited by the 
availability of tumor models. For decades, established cancer cell lines 
represented the mainstay preclinical tumor model, but they show limitations, 
such as limited capacity to recapitulate inter- and intra-tumor heterogeneity, 
adaptation to grow in two-dimensional cultures and the lack of interaction with 
the microenvironment. To overcome these restraints, patient-derived tumor 
xenografts (PDX) have been developed in recent years. Although they mirror 
histological and molecular features of the patient’s tumor, PDXs also have 
limitations including maintenance costs and unsuitability for large-scale 
screenings. Here we describe a novel platform of PDX-derived cell lines, that 
retain the genomic and pharmacologic profile of the sample of origin and offer 
advantages such as reduced working costs and ease of handling. In 
conclusion, we provide a valuable preclinical model for large-scale functional 
gene validation and assessment of novel therapeutic strategies in colorectal 
cancer. 
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ABSTRACT 
 
PURPOSE: Patient-derived xenograft (PDX) models accurately recapitulate 
the tumor of origin in terms of histopathology, genomic landscape, and 
therapeutic response, but they also retain some limitations due to costs 
associated with their maintenance and restricted amenability for large-scale 
screenings. To overcome these issues, we established a platform of 2D cell 
lines (xeno-cell lines, XLs), derived from PDXs of colorectal cancer (CRC) 
whose patient germline gDNA was available. 
EXPERIMENTAL DESIGN: Exome and expression analysis were performed. 
Biomarkers of response and resistance to anti-HER therapy were annotated. 
RESULTS: Molecular features were remarkably concordant between PDXs 
and matched cell lines. XLs recapitulated the entire spectrum of CRC 
transcriptional subtypes. Exome and RNA-seq analyses delineated several 
molecular biomarkers of response and resistance to EGFR and HER2 
blockade. Genotype-driven responses observed in vitro in XLs were 
confirmed in vivo in the matched PDXs.  
CONCLUSION: The XL platform represents a preclinical tool for functional 
gene validation and proof of concept studies to identify druggable 
vulnerabilities in CRC. 
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1. Introduction 
 
The awareness that cancer is a genetic disease and the availability of 
genomic profiles of tumor samples paved the way to ‘precision medicine’ in 
oncology (1). 
In the last ten years, major advances in complex genomic technologies have 
strongly contributed to the mapping of cancer molecular landscape (2). The 
need to understand the impact of the major drivers of cancer development 
and progression on therapeutic intervention has thus become of paramount 
importance. Functional characterization and target validation has required 
generation of reliable cellular and animal models to understand the role of 
genomic alterations on tumor onset and evolution (3). Functional studies have 
proven that the tumor is often dependent on oncogenic alterations for its 
growth and maintenance, providing a strong rationale for the development of 
therapies targeting cancer driver genes (4). 
On these premises, modeling disease-associated alterations in models that 
reflect the clinical features of patients is vital to implement precision medicine. 
So far, different cellular and animal models have been generated, each 
showing both advantages and pitfalls. 
 
Cancer cell lines have been extensively and routinely used for biomarker 
discovery and drug development. Indeed, the Cancer Cell Line Encyclopedia, 
the Genomics of Drug Sensitivity in Cancer (GDSC) Sanger Institute project, 
the National Cancer Institute-60 (NCI-60) cancer cell line screen, and the 
Cancer Therapeutic Response Portal (CTRP) constitute paradigmatic 
examples of how coupling cell lines to systematic compound screening can 
provide an informative clinical platform for pharmacogenomic analysis (5-9). 
Although these studies aim at providing tools to predict anti-cancer drug 
response, their complete success is limited by several intrinsic characteristics 
of cell lines, such as limited capacity to recapitulate inter- and intra-tumor 
heterogeneity and adaptation to growing in artificial conditions. Genomic 
instability, loss of molecular heterogeneity and lack of the tumor 
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microenvironment represent the three main issues thought to make a 2D cell 
line model divergent from the original tumor; for these reasons, the clinical 
relevance of cell line models has been repeatedly questioned (10). These 
drawbacks may play against the recapitulation of the evolutionary nature of 
cancer itself, thus limiting the translation of the in vitro results to the clinical 
response of the tumor in the patient. In addition, the frequent unavailability of 
matched germline tissue has often hampered the confident identification of 
somatic changes.   
 
To obviate these issues and better bridge the bench-to-bedside gap, patient-
derived tumor xenografts (PDXs, xenopatients) have been developed. 
Although these models had already been described in the seventies, they 
have become popular for assessing genotype-drug correlation response 
studies in the last decade (11). Comprehensive genetic and transcriptomic 
studies have demonstrated that PDXs maintain the majority of genetic 
alterations and global pathway activity of primary tumors (12,13); importantly, 
the histological structure and intratumoral clonal heterogeneity are usually 
also preserved (14,15), although recent literature reports the selection of 
specific copy number alterations during PDX propagation (16). In colorectal 
cancer (CRC), seminal studies have already set the stage for 
pharmacogenomic analyses and association of PDX genotype with targeted 
therapy response (12,17). PDXs have significantly contributed to shedding 
light on the mechanisms of resistance and on identification of predictive 
biomarkers of response, but large-scale screening is actually limited by the 
costs, size and efforts for animal maintenance and manipulation.  
 
New models that can couple both the ease of handling of cell cultures with the 
preservation of intra-tumor heterogeneity of PDXs have been proposed. 
Bruna and colleagues (5) have generated a large biobank of breast cancer 
PDXs combined with short-term cultures of PDX-derived cells demonstrating 
that the corresponding cell models could be reliably used to assess drug 
response and to identify biomarkers of resistance in vitro, as paralleled in 
vivo. Similar studies have been recently performed also in gastrointestinal and 
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pancreatic cancer (18,19), thus confirming the value and applicability of this 
approach. 
 
In this work, we describe the establishment of a panel of 29 cell lines obtained 
from a cohort of 29 CRC PDXs and provide a comprehensive genomic 
analysis of these models. Importantly, we show that the molecular features of 
xenopatient-derived cell lines closely parallel their matched PDX models. We 
also show that PDX-derived cell lines constitute a valuable model to 
interrogate CRC patient molecular vulnerabilities and provide an effective 
opportunity to reveal patient-specific drug responses and implement precision 
oncology in CRC. 
 
2. Materials and Methods 
Xenopatient-derived cell line establishment, culture and authentication 
For xenopatient generation, fresh surgically resected primary CRC and 
metastases tissues or biopsies were obtained and collected from consenting 
patients. All procedures were approved by the Italian Ministry of the Health 
and the Ethics Committee of the Medical faculty of the University of Rostock, 
in accordance with generally accepted guidelines for the use of human 
material. 
Tumor specimens were cut into small pieces and either frozen (biobanked) or 
prepared for implantation, as previously described (12,20). For tumor 
implantation, six-week-old female NMRI nu/nu or NOD/SCID mice were used 
as recipients. All experimental procedures were carried out in strict 
accordance with the recommendations in the Guide for the Care and Use of 
Laboratory Animals of the National Institutes of Health. The protocol was 
approved by the Committee on the Ethics of Animal Experiments of the 
University of Rostock and the Internal Ethical Committee from Animal 
Experimentation of the Candiolo Cancer Center.  
Established tumors from xenopatients (1500 mm3) were removed and 
processed for in vitro culture as described below. 
PDX tissues were dissociated into single-cell suspension by mechanical 
dissociation using the Gentle MACS Dissociator (Miltenyi Biotec) and 
enzymatic degradation of the extracellular matrix using the Human Tumor 
Dissociation Kit (Miltenyi Biotec) according to the manufacturer’s protocol. 
Cell suspension was centrifuged three times and finally the pellet was re-
suspended with DMEM/F12 medium containing 10% FBS and 2 mM L-
glutamine. The final cell suspension was then filtered through a 70-um cell 
strainer (Miltenyi Biotec) and cells that were not filtered out were re-
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suspended in DMEM/F12 medium containing 10% FBS, 2mM L-glutamine, 
antibiotics (100 U/ml penicillin and 100 mg/ml streptomycin) and 10 μM ROCK 
inhibitor Y-27632 (Selleck Chemicals Inc) and cultured on collagen-coated 
plates (Corning) at 37°C in a humidified atmosphere of 5% CO2. Medium was 
changed regularly every three days. Growing cell lines were further passaged 
and were subjected to three sequential cycles of freezing and thawing to 
ensure the stability of the cell lines. Growing cell lines were stocked at low 
passages by cryopreservation.  
Only in one case (CRC0080), the cell line was established as xenosphere 
(21) and then adapted to grow in 2D as monolayer. HROC cell lines collection 
was derived by Michael Linnebacher’s laboratory, as previously reported (20). 
BT474 and SKBR3 cell lines were purchased by American Type Culture 
Collection (ATCC) and maintained in DMEM/F12 and DMEM media, 
respectively, containing 10% FBS, 2mM L-glutamine, antibiotics (100 U/ml 
penicillin and 100 mg/ml streptomycin) and cultured at 37°C in a humidified 
atmosphere of 5% CO2.  
XLs were routinely checked for mycoplasma contamination using the Venor 
GeM Classic Kit (Minerva Biolabs), according to the manufacturer’s protocol. 
XLs, matched PDXs and patient authentication was performed using the 
Gene Print 10 System (Promega), through Short Tandem Repeats (STR) at 
10 different loci (D5S818, D13S317, D7S820, D16S539, D21S11, vWA, 
TH01, TPOX, CSF1PO and amelogenin). Amplicons from multiplex PCRs 
were separated by capillary electrophoresis (3730 DNA Analyzer, Applied 
Biosystems) and analysed using GeneMapperID v.3.7 software (Life 
Technologies). 
 
DNA extraction and MSI analysis 
Genomic DNA samples were extracted from each XL and matched PDX using 
ReliaPrep gDNA Tissue Miniprep System (Promega). Patient’s germline 
genomic DNA obtained from normal tissue (liver) or PBMCs of each patient 
was used as reference genome.  
The MSI status was evaluated by mean of MSI Analysis System kit 
(Promega), according to manufacturer’s protocol. The analysis requires a 
multiplex amplification of seven markers including five mononucleotide repeat 
markers (BAT-25, BAT-26, NR-21, NR-24 and MONO-27) and two 
pentanucleotide repeat markers (Penta C and Penta D). The products were 
analyzed by capillary electrophoresis in a single injection using ABI 3730 DNA 
Analyzer capillary electrophoresis system (Applied Biosystems). The results 
were analyzed using GeneMapper V5.0 software. Sample with instability in 
one or more markers are defined as MS-instable (MSI-H). Sample with no 
detectable alterations are MS-stable (MSS). 
MSI events were evaluated by MSIsensor (22). Signatures were calculated 
using a custom Python script. 
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Exome sequencing and bioinformatic analysis 
Exome sequencing was performed in outsource, while data analysis was 
performed at the Candiolo Cancer Institute. Each triplet of DNA samples 
(PDX, xeno-cell line, germline) was sent to GATC (Kostanz, DE) that 
performed library preparation, exome capture, sequencing on Illumina 
platform and data demultiplexing. Contaminating mouse reads were removed 
using Xenome (23). Human sequences were mapped to the hg38 human 
reference by BWA-mem (24) and PCR duplicates were removed using Picard 
Mark Duplicates function (broadinstitute.github.io/picard/). Somatic mutational 
and gene copy number profiles for each XL and matched PDX were obtained 
subtracting germline profiles as previously described (25).  
 
Gene copy number analysis  
Real-time PCR was performed with 10 ng of DNA per single reaction using 
GoTaq QPCR Master Mix (Promega) with an ABI PRISM 7900HT apparatus 
(Applied Biosytems; primers’ sequences are available on request). Gene copy 
numbers were normalized to a control diploid cell line, HCEC. 
 
RNA extraction, analysis and identification of cancer-cell intrinsic 
subtypes 
RNA was extracted using miRNeasy Mini Kit (Qiagen), according to the 
manufacturer’s protocol. The quantification and quality analysis of RNA was 
performed on a Bioanalyzer 2100 (Agilent), using RNA 6000 nano Kit 
(Agilent). Total RNA extracted from XLs was processed for RNA-seq analysis 
with the TruSeq RNA Library Prep Kit v2 (Illumina) following manufacturer’s 
instruction and sequenced on a NextSeq 500 system (Illumina). Each fastq 
file was aligned using MapSplice (26). Version hg19 of the genome was used 
and Gencode v19 as reference transcriptome database and gene 
quantification was performed with RSEM (27). Assignments of each xeno-cell 
line to cancer-cell intrinsic subtypes and consensus molecular subtypes were 
performed as previously described (28,29). Hierarchical clustering of 
Xenopatient and matching XenoLine samples was performed with maximum 
cosine distance using the GEDAS software (30) based on genes whose 
variance in log2 expression signal was greater than 0.5 in both the 
Xenopatient and the XenoLine datasets and on CRIS geneset.  
 
Drug proliferation assays  
CRC XLs were seeded at different densities (5–7 x103 cells per well) in 100 μl 
complete growth medium in 96-well plastic culture plates at day 0. The 
following day, serial dilutions of the indicated drugs were added to the cells in 
serum-free medium, while medium-only was included as controls. Plates were 
incubated at 37 °C in 5% CO2 for 5 or 6 days, after which cell viability was 
assessed by measuring ATP content through Cell TiterGlo Luminescent Cell 
Viability assay (Promega). Luminescence was measured by SPARK M10 
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(Tecan) plate reader. Treated wells were normalized to untreated/DMSO 
treated wells. 
For long-term proliferation assays, cells were seeded in 24-wells plates (1x104 
cells per well) and cultured in the absence and presence of drugs as 
indicated. Wells were fixed with 3% paraformaldehyde (Santa Cruz) and 
stained with 1% crystal violet-methanol solution (Sigma-Aldrich) after 2 
weeks. All assays were performed independently at least three times.  
Cetuximab and trastuzumab were obtained from the Pharmacy at Niguarda 
Cancer Center in Milan, Italy. Lapatinib was purchased from Selleck 
Chemicals. 
Lentiviral Transduction of HER2 Mutant Colorectal XL-cells 
The PIK3CA p.H1047R mutation was inserted into pLenti-PIK3CA-myc-DDK 
vector (Origene) using site directed mutagenesis with the Quick Change II 
Site-Directed Mutagenesis kit (Agilent), according to manufacturer’s 
instructions. Primers sequences for PIK3CA site directed mutagenesis were 
the following: GAAACAAATGAATGATGCACGTCATGGTGGCTGGACAAC 
(PIK3CA_H1047R_F) and 
GTTGTCCAGCCACCATGACGTGCATCATTCATTTGTTTC 
(PIK3CA_H1047R_R). Lentiviral control pLenti-myc-DDK vector was 
purchased from Origene. 
Lentiviral control vectors (pRLL empty and FG12 empty), pRLL-KRAS WT, 
pRLL-KRAS G13D and FG12-BRAF V600E vectors were previously exploited 
(31,32). 
Lentiviral vector stocks were produced by transient transfection of the transfer 
plasmids, the packaging plasmids pMDLg/pRRE and pRSV.REV, and the 
vesicular stomatitis virus (VSV) envelope plasmid pMD2.VSV-G  (12, 5, 2.5, 
and 3 μg, respectively, for 10 cm dishes) in HEK-293T cells. Determination of 
the viral p24 antigen concentration was done by ALLIANCE HIV-I P24 ELISA 
2 PLATE KIT (PerkinElmer Life Science Inc.). Cells were transduced in six-
well plates (3 × 105 per well in 2 ml of medium) in the presence of polybrene 
(8 mg/ml) (Sigma).  
 
Western blotting analysis  
Total cellular proteins were extracted by solubilizing the cells in boiling SDS 
buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, and 1% SDS). Extracts were 
clarified by centrifugation and protein concentration was determined using 
BCA Protein Assay Reagent kit (Thermo). Western blot detection was 
performed with enhanced chemiluminescence system (GE Healthcare) and 
peroxidase conjugated secondary antibodies (Amersham). The following 
primary antibodies were used for western blotting (all from Cell Signaling 
Technology, except where indicated): anti-phospho-HER2 YY1221/1222); 
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anti-HER2 (Santa Cruz); anti-phospho-EGFR (Y1068); anti-EGFR (clone 
13G8, Enzo Life Science); anti-vinculin (Millipore); anti-phospho-p44/42 ERK 
(Thr202/Tyr204); anti-p44/42 ERK; anti-phospho AKT (Ser473); anti-AKT; 
anti-PTEN; anti-HSP90 (Santa Cruz); anti-GAPDH (Abcam).  
 
In vivo treatment 
Established tumors (average volume 400 mm3) were treated with the following 
regimens, either single-agent or in combination: lapatinib (Carbosynth) 100 
mg/kg, daily (vehicle, 0.5% methylcellulose, 0.2% Tween-80); trastuzumab 
(Roche), 30 mg/kg once weekly (vehicle: physiological saline). Tumor size 
was evaluated once weekly by caliper measurements, and the approximate 
volume of the mass was calculated using the formula 4/3 (d/2)2 D/2, where d 
is the minor tumor axis and D is the major tumor axis. Animal procedures 
were approved by the Ethical Commission of the Candiolo Cancer Institute 
and by the Italian Ministry of Health. 
 
Statistical Analysis 
Results were expressed as means ± standard error of the mean (SEM) or 
standard deviation (SD) as indicated in the legend. Statistical significance was 
evaluated by t test or two-way ANOVA, using GraphPad Prism software. 
P<0.05 was considered statistically significant.  
 
3. Results 
 
Establishment of PDX-derived cell lines 
We derived primary cell lines from a set of CRC PDX models with the goal of 
setting up a platform of in vitro CRC preclinical models closely resembling 
patient’s features. The clinico-pathological characteristics of patients from 
whom the PDXs were initially obtained are listed in Supplementary Table S1; 
the establishment procedure, described in detail in the ‘materials and 
methods’ section, is schematically represented in Supplementary Fig. S1. 
Briefly, the PDX tumor is surgically excised and mechanically and 
enzymatically dissociated, to obtain cells that are subsequently cultured in 2D 
petri dishes. In this work, a total of 29 primary cell lines have been derived 
from a collection of 29 PDXs established at the Candiolo Cancer Institute (n= 
17) and at Rostock University (n=12) (12,17,20). Among the 29 PDXs, 10 
were originated from primary tumors and 19 from liver or peritoneum 
metastases of 28 CRC patients (two different metastatic lesions - IRCC-5A 
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and IRCC-5B - were obtained from the same patient) (Fig. 1A and 
Supplementary Fig. S1). To underline the origin of these 2D primary cell lines 
from xenopatients, we will refer to them as xeno-cell lines (XLs). 
 
XLs, although presenting cell-specific morphological features, displayed a 
predominant and typical epithelial pattern characterized by islets of compact 
or round shaped cells growing predominantly as a monolayer or, in one case 
(HROC147), as cell-clumps in suspension (Supplementary Fig. S2). The 
epithelial phenotype was confirmed by analysis of expression of specific 
epithelial markers (e.g. E-cadherin, cytokeratin 8, 18 and 19 and EpCAM) with 
respect to mesenchymal markers (e.g. vimentin, SNAIL and TWIST1) 
(Supplementary Fig. S3). 
All 29 XLs displayed the ability of long-term propagation (multiple passages) 
in vitro and their stability was ensured by at least three sequential 
freezing/thawing cycles prior to bio-banking. Cells were maintained in culture 
for at least 8 passages prior to nucleic acid extraction.  
 
Xeno-cell lines recapitulate the genomic landscape of matched patient-
derived xenografts 
To assess whether the CRC molecular subtypes that are commonly 
ascertained in the clinic were preserved in both the PDXs and the matched 
2D XLs, we performed genomic and transcriptomic analyses systematically 
comparing the two preclinical platforms. 
 
Initially we analyzed microsatellite markers and found that 5 out of 29 (17%) 
PDXs displayed microsatellite instability (MSI-H), while the remaining were 
microsatellite stable (MSS). The MSI status was maintained in the matched 
XLs (Fig. 1B)(33).  
RNA expression-based correlation analysis between XLs and their originating 
PDXs, which had been subject to gene expression analysis in a previous 
independent study (28), revealed higher correlation between matched XL-
PDX pairs than between unmatched pairs (Kolmogorov-Smirnov, P < 1x10-16, 
Supplementary Fig. S4A); furthermore, hierarchical clustering always 
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preferentially aggregated each XL with the PDX sample of origin 
(Supplementary Fig. S4B). 
 
Next, parallel exome sequencing analyses of XLs and matched PDXs were 
performed. Importantly, to identify tumor-specific somatic mutations, germline 
genomic DNA (gDNA) extracted from normal tissues (liver) or blood (PMBCs) 
of the patient was used as reference genome.  
Samples were sequenced with high depth and coverage to allow detection of 
low-frequency somatic mutations in xenopatient tumors and matched XLs 
despite contamination of human cancer cells with murine infiltrating cells in 
some samples. The median depth achieved was 143x and the median 
coverage was 97.8% on the coding regions of the reference genome 
(assembly hg38) with 90.3% of the bases covered at least 40 times. 
 
A high level of correlation was found between cell lines and matched PDXs 
regarding the total number of somatic nonsynonymous single-nucleotide 
variants (SNVs) and insertions or deletions (INDELs) (Pearson r=.9870; 
P<.0001) (Supplementary Fig. S5A). Overall, somatic mutations detected in 
PDXs are highly preserved in cell lines (Supplementary Fig. S5B). 
MSI-H models showed a higher number of MSI events compared to MSS 
cases (median value MSI-H = 7723.5 vs MSS = 263.5) (Fig. 1C). Moreover, 
the number of MSI events is maintained in each PDX and matched xeno-cell 
line (Pearson r=.998), in both MSS and MSI-H cases.  
MSI-H cell lines and matched PDXs displayed a hypermutator phenotype with 
a higher mutational load (number of mutations/Mb) as compared to MSS 
models (median value MSI-H = 60.5 vs MSS = 5.5) (Fig. 1D), reflecting a 
higher number of non-synonymous single nucleotide variations (SNVs) 
(mutation burden) (median value MSI-H = 1691.5 vs MSS = 116) (Fig. 1E). 
This is consistent with the reported mutation frequency in CRC tissues and 
cell lines (2,7,34). No MSS model was found to be hypermutated, likely 
reflecting the lack of mutations in POLE or POLD1, which are known to 
generate mutations in the absence of MSI-H (2). Moreover, the INDEL burden 
was higher in MSI-H rather than MSS models (median value MSI-H = 562.5 
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vs MSS = 7), as previously reported in TCGA cancers and CRC cell lines 
(2,34) (Fig. 1E and Supplementary Fig. S5C).  
Somatic variants within the coding regions in XLs were highly concordant with 
the corresponding xenopatient specimens for both MSS and MSI-H models 
(median value = 0.78 frequency of concordance, range 0.48-0.93) 
(Supplementary Fig. S5D). The allelic frequencies of alterations shared 
between XLs and corresponding PDXs were significantly correlated (Pearson 
correlation coefficient r = 0.8233)(Supplementary Fig. S5E).  
Despite the global genetic correlation between the two models, we also 
detected some divergent mutations identified only in XLs or in PDXs (private 
mutations). The putative biological significance in cancer of these private 
mutations identified only in XLs (n=4174) or PDXs (n=1997) was assessed on 
Cancer Gene Census and data reported from CRC analysis (35,36). Only 
5.6% (234/4174) of divergent mutations found in XLs affected cancer-related 
genes. Similarly, cancer-related genes that were discordant in the PDXs 
represented 5.2% (104/1997) (Supplementary Table S2). Of note, 74.04% 
(77/104) and 79.91% (187/234) of private mutations affecting cancer-related 
genes were identified in MSI-H PDXs and XLs, respectively. Moreover, private 
mutations had a median VAF of 31.69% and 32.88% for XLs and PDX, 
respectively (Supplementary Table S2).  
While the SNVs spectrum was maintained between XLs and matched PDXs, 
it differed significantly between the MSI-H and MSS cases, with an increased 
proportion of C>G/G>C transversion (about 5-fold) and a decrease in 
T>C/A>G transition in the MSS cases (about 1.3-fold, Fig. 1F). Interestingly, 
MSI-H models present a SNV spectrum typically associated with defective 
DNA mismatch repair and found in microsatellite unstable CRCs (37) 
(Supplementary Fig. S6).   
 
Finally, exome analysis revealed, when considering copy number variation 
(CNV) profiles, that the copy number profile of each PDX is also maintained in 
each derived cell line (Pearson correlation 0.82 ≤ r ≤ 0.98). As expected, MSS 
xenopatients and matched XLs displayed a higher level of segments of loss of 
heterozygosity (LOH) or copy-number variations than MSI models, which 
showed a more stable CNV profile (Fig. 2A). In MSS cases, the most common 
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deleted chromosomal arms were 8p, 17p (including TP53), and 18q (including 
SMAD4), and the most common gained regions were chromosome 7, 8q 
(including MYC), 13, and 20q (Fig. 2B and 2C).  
 
 
CRC pathway alterations are conserved in xeno-cell lines 
Integration of genomic results allowed the identification of deregulated 
signaling pathways; the genes most commonly altered in CRC (2) were all 
represented in our panel of PDXs and matched cell lines (Fig. 3A). In 
particular, recurrent alterations in the DNA mismatch repair (MMR), WNT, 
MAPK, PI3K/PTEN, TGF- and p53 pathways were identified (Fig. 3A). 
 
Mutations in MMR genes were found in MSI-H tumors. These alterations 
involve missense mutations in MSH2, MSH3, MSH6 and POLE/POLD1 
genes, as well as MLH1 expression downregulation (Fig. 3A). Interestingly, 3 
MSS cases displayed alterations in MSH3, MSH6 and POLE MMR-associated 
genes in both xenopatients and matched XLs. These mutations were not 
reported previously, nor did they fall in regions important for protein activity, 
suggesting that these genes are not functionally affected by these mutations. 
 
The WNT pathway is frequently altered (90%) in CRC. The most frequent 
alterations include inactivating mutations in APC as well as activating 
mutations in CTNNB1 (2). Other variants affecting this pathway are 
inactivating mutations targeting regulators of the Wnt pathway, such as 
TCF7L2, FBXW7, AXIN2 and RNF43 genes. 
APC mutants were identified in 14 out 29 cases (48.28%), while other 
alterations were found in the same pathway in wild-type APC cases, such as 
a FBXW7 alteration (p.R465H) found in one case, and an  AXIN2 
downregulation or mutation (p.G495A) in other three cases. Similarly, RNF43 
alterations were identified in one MSS APC wild-type cell line and in four out 
of five microsatellite unstable cases, highlighting the association of these 
alterations with the MSI-H phenotype, as previously reported (38). Of interest, 
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multiple alterations affecting this gene co-occurred in two APC wild-type 
cases. 
In addition, a specific translocation of the Wnt-agonistic RSPO3 with PTPRK 
was found in one BRAF-mutated APC wild-type case, as assessed by RNA-
seq analysis on XLs and validated by quantitative RT-PCR (Fig.3B and 
Supplementary Fig. S7A and S7B). No RSPO2 gene fusions were identified in 
our collection of XLs. 
We also evaluated the genetic status of TP53 that resulted altered in 79.3% of 
cases (23/29). In addition, alterations in ATM were found in 10.35% (3/29), 
one of these co-occurred with a TP53 mutation, while the remaining two 
cases were TP53 wild-type. 
The TGF-β signaling pathway is also frequently deregulated in CRC (2). In 
our dataset, we identified 2 TGFBR1 mutated cases and four cases carrying 
TGFBR2 alterations. Consistent with previous findings (39), all of these 
models were MSI-H. Moreover, alterations in SMAD4 were identified in 7 
cases, while other 4 cases (CRC0781-XL, CRC0691-XL, HROC59 and 
HROC239) did not express SMAD4, as assessed by RNA-seq analysis (Fig. 
3A and Supplementary Fig. S7C); lack of SMAD4 expression was ascribed to 
LOH in three cases (Fig. 2C). No alterations in SMAD2 and SMAD3 were 
found; three MSI-H cases (IRCC-1-XL, HROC131 and HROC285) displayed 
deletions in the ACVR2A gene, a TGF-β family member, known as a potential 
player in CRC (2). 
 
Genetic alterations in RAS-MAPK and PI3K-PTEN pathways are very 
frequent in CRC. Activating mutations in KRAS - including the less common 
mutations p.Q61K (exon 3), p.K117N and p.A146V (exon 4) -  and in NRAS 
were identified in 13 out 29 XLs and matched PDXs, thus reflecting the  
prevalence of RAS mutations found in CRC patients. We identified five 
models harboring BRAF p.V600E mutations, two derived from MSS 
metastases and 3 from primary MSI-H CRC. While alterations in KRAS, 
NRAS and BRAF displayed a significant pattern of mutual exclusivity, 2 out of 
ten KRAS mutated models displayed also co-occurring activating mutations in 
the PIK3CA gene (codon 1047 and 1049). Only one PIK3CA variant 
(p.H1047R) was identified in a KRAS/NRAS/BRAF wild-type case. 
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Missense (p.A86E and p.D92Y) as well as nonsense (p.R233*) mutations 
affecting the PTEN gene were identified in three cases. Although both 
missense mutations fall in the proximity or within the WPD loop of the catalytic 
site, only alterations in codon 92 were reported to fully abrogate PTEN 
function (40). In addition, western blot analysis highlighted the loss of PTEN 
expression in two xeno cell lines, CRC0394-XL carrying the p.R233* 
nonsense mutation, and HROC277, in which PTEN expression was 
consistently decreased at the transcript level due to genetic loss of the PTEN 
locus (Fig. 2C, Supplementary Fig. S7C and S7D). 
Alternative ways of activation for PIK3CA pathway include transcriptional 
upregulation of IGF2 (Supplementary Fig. S7E). In our panel of XLs, we 
identified seven cases (CRC0081-XL, CRC0438-XL, HROC46, 
HROC278Met, HROC59, HROC239 and HROC285) overexpressing the IGF2 
transcript, as assessed by RNA-seq analysis (log2 ratio > 1.5) 
(Supplementary Fig. S7E). Of note, overexpression of IGF2 was not 
associated to genomic amplification of the IGF2 gene, as previously reported 
(Fig. 2C) (2,41).  
 
Other identified alterations in the MAPK pathway included an activating 
mutation (p.K57N) in MAP2K1 (encoding the protein MEK1) observed in one 
XL and its matched PDX (CRC0740).   
 
Evaluation of genetic alterations in receptors of the ERBB family receptors 
unveiled the presence of an EGFR extracellular mutation (p.G465E) in a 
PIK3CA-mutated case (CRC0104-XL). Of interest, this EGFR mutation was 
previously found to be associated with acquired resistance to anti-EGFR 
therapies (42,43). Indeed, its corresponding xenopatient was established from 
a liver metastasis of a patient who had received cetuximab treatment within 
six months prior to resection (17). 
 
Another clinically actionable ERBB family member frequently altered in cancer 
is ERBB2 (also known as HER2); ERBB2 gene amplification was identified in 
two MSS wild-type RAS/BRAF cases (CRC0080-XL and CRC0186-XL) (Fig. 
2C and Supplementary Fig. S8A). Interestingly, CRC0186-XL showed a 
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remarkable increase in ERBB2 gene copy number (n=33.2), while CRC080-
XL displayed a less pronounced increase (n=6.1), comparable to that present 
in the breast cancer cell lines BT474 and SKBR3 (n=6.5 and n=5.6, 
respectively) (Supplementary Fig. S8B). In these cell lines, ERBB2 gene copy 
number gain led to protein overexpression (Supplementary Fig. S8C). 
Moreover, CRC0080-XL carried also an ERBB2 activating mutation (p.L866M) 
affecting the intracellular kinase domain of the receptor (44) (Fig. 3A). 
Mutations in the extracellular region of the ERBB2 receptor (p.S310F and 
p.L465V) were identified in two additional xenopatients and matched cell lines 
(HROC87 and HROC112Met, respectively). Of note, ERBB2 p.S310F was co-
present in a BRAF p.V600E mutated case. Similarly, in another BRAF 
mutated case (HROC131), we identified co-occurrence of the ERBB3 
p.V104M variant (Fig. 3A).    
 
Finally, expression analysis revealed that molecular subtypes found in XLs 
correlated with transcriptional classes identified by the recently described 
CRC intrinsic subtype (CRIS) analysis (28) (Fig. 3A and C). Indeed, 
hierarchical clustering based on CRIS-classifier genes, as already seen for 
the whole transcriptome, preferentially clustered XLs with the PDXs of origin 
(Supplementary Fig. S4). In total, 26 out of 29 XLs were significantly assigned 
to a specific CRIS class (Supplementary Table S3). In particular, MSI-H and 
KRAS/BRAF mutant cells were enriched in CRIS-A, while CRIS-C included 
KRAS/BRAF-WT lines. In addition, 2 cell lines that displayed TGF-β pathway 
alteration clustered in CRIS-B and IGF-2 overexpressing cells were included 
in CRIS-D group (Fig. 3 and Supplementary Table S3). A similar distribution in 
genetic alterations was also found for the consensus molecular subtypes 
(CMS): MSI and BRAF mutational status were enriched in CMS1, and KRAS 
mutant model were partially depleted in CMS2.  
Of note, associations between CRIS and CMS transcriptional classes are also 
evident. Indeed CRIS-A samples are assigned to CMS1 and CMS3, while 
CRIS-C is predominantly composed of CMS2. Interestingly, in the context of 
stromal depleted samples, CRIS-D samples are also classified as CMS4, 
likely due to the similarities in stem cells rewiring program in intrinsic cancer 
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cell intrinsic traits – i.e. LGR5 pathway – captured by the two classifiers. (Fig. 
3C). 
 
Sensitivity to EGFR blockade is maintained in xeno-derived cell lines 
Anti-EGFR monoclonal antibodies are approved to treat metastatic CRC and 
achieve a 10% objective response rate in unselected patients treated with 
antibody monotherapy (45). Clinical benefit to EGFR blockade increases up to 
25% of cases when tumors are stratified for wild-type KRAS, NRAS and 
BRAF (45). To assess whether XLs could recapitulate this genotype-drug 
response, and therefore could be exploited as a reliable platform for drug 
testing, we checked the entire cell platform for cetuximab sensitivity.  
 
Based on the level of response to cetuximab, the cell collection was classified 
in 3 different groups: sensitive (n=2), intermediate (n=5) and resistant (n=22) 
(Fig. 4). As observed in the clinic, KRAS, BRAF or NRAS mutations, as well 
as other genetic alterations (i.e. MAP2K1 p.K57N and EGFR p.G465E) 
associated with resistance to EGFR blockade in CRC cells (Fig. 4) 
(17,25,42,46). Similarly, ERBB2-amplified CRC0186-XL was refractory to 
cetuximab treatment, confirming previous findings obtained by pre-clinical and 
clinical data from the same individual patient (12,17). Conversely, the other 
ERBB2-amplified and mutated CRC0080-XL cell line displayed higher 
sensitivity to cetuximab treatment. 
 
Integration of multi-layer data revealed also a positive correlation with the 
transcriptional classes obtained from the cancer cell intrinsic classifier 
(Supplementary Table S3). As previously reported, CRIS-A resulted enriched 
in both MSI-H and KRAS/BRAF mutated cases (IRCC-1-XL, HROC50, 
HROC277, HROC147, CRC0438-XL and CRC0781-XL) with marked 
resistance to cetuximab treatment (Fig. 3C), and CRIS-C depleted for KRAS 
mutant cells (IRCC-5A-XL, IRCC-5B-XL, CRC0078-XL, CRC0080-XL and 
CRC394-XL), showing sensitivity to anti-EGFR treatment. Confirming 
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previous evidences(28,47), both CRIS-C and CMS2 transcriptional classes 
are enriched for cetuximab responsive models (Supplementary Table S4). 
 
Expression analysis identifies therapeutic targets in xeno-derived cell 
lines 
RNA-seq data analysis unveiled potentially actionable targets in the XL 
platform. Since receptor tyrosine kinases are often implicated in cancer and 
are ideally suited for pharmacological inhibition, the analysis was focused on 
this class of proteins. Overall, 30 distinct RTKs passed the filtering process 
during RNA-seq analysis due to their expression level in our XL collection. 
Outlier expression analysis identified ten (log2 ratio ≥ 3.5) overexpressed 
receptor tyrosine kinase genes including ERBB2, AXL, FGFR1, NTRK1, 
NTRK2, ROR2, RET, EPHA4, EPHB1 and EPHB6 in individual xeno-derived 
cell lines (Fig.5).   
Among these, only two identified RTKs were overexpressed in RAS/RAF wild-
type cells (“WT-specific” RTKs), namely NTRK1 (TRKA) and ERBB2 (HER2). 
Integrated analysis showed that their overexpression is associated to different 
molecular alterations, namely, gene translocation (NTRK1) or gene 
amplification (ERBB2) respectively (Fig. 5 and Supplementary Fig. S8A, S8B 
and S9).  
 
In the TRKA overexpressed case, we identified a genetic rearrangement 
involving exon 10 or 11 of LMNA and exon 11 of NTRK1 genes (48,49). The 
two distinct splice variants encoding exons 1-10 or 1-11 of LMNA gene fused 
to exons 11-16 of NTRK1 gene reported in the donor patient were identified 
by RNA-seq analysis in the matched xeno cell line (Supplementary Fig. S9). 
Remarkably, the pharmacological response of these xeno-cells resembled the 
one observed in the corresponding PDX upon entrectinib treatment (48). 
 
In order to validate ERBB2 amplification as an actionable target, we first 
evaluated biochemical pathway activation. In contrast to CRC0186-XL, 
CRC0080-XL showed lower level of HER2 protein, but still an active 
downstream pathway due to the presence of the L866M mutation 
(Supplementary Fig. S8C).  
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This analysis confirmed that overexpression and constitutive signaling as well 
as downstream pathway activation of HER2 paralleled the extension of 
ERBB2 gene amplification. 
 
To validate overexpressed ERBB2 as putative target for pharmacological 
inhibition (12), we challenged our in vitro models with rational combinations of 
drugs. We initially tested the effect of drugs (lapatinib and trastuzumab) that 
have previously shown activity on HER2 positive metastatic CRC patients 
(12,50). While monotherapy showed no or mild effects, both lines (CRC0080-
XL and CRC0186-XL) displayed significant sensitivity to the combinatorial 
treatment (Fig. 5C) in short-term proliferation assays. We performed western 
blot analysis showing that the biological effect of the drugs on ERBB2-
amplified CRC cell lines is matched by the quenching of HER2 biochemical 
downstream signals (Fig. 5D). Of note, similar results were also obtained in 
vivo, when the corresponding ERBB2-amplified xenopatients were challenged 
with the same treatments for 28-35 days (51) (Fig. 5E), thus confirming the XL 
as a valuable preclinical model to assess drug response and to dissect 
biochemical pathway activation.  
 
Combinatorial treatment with lapatinib and trastuzumab of HER2+ patients 
has been exploited in the recently completed proof-of-concept clinical trial 
named HERACLES (50). Our previous work based on liquid biopsy analysis 
has shown that 32 out of 35 patients treated with anti-HER2 inhibitors 
relapsed after initial response revealing the presence of molecular 
mechanisms potentially responsible for resistance (primary or acquired) to 
HER2 blockade (52). In particular, either KRAS or BRAF mutated clones were 
preferentially found in patients who were initially refractory to anti-HER2 
treatment (primary resistance), while PIK3CA mutations were detected at 
progression in patients who had responded to lapatinib+trastuzumab 
combinatorial treatment and then relapsed (acquired resistance). In order to 
validate these genetic players as putative drivers of resistance, we transduced 
HER2+ CRC XL-cells by means of lentiviral vectors and performed 
pharmacological and biochemical analysis of treated cells. We found that 
overexpression of mutant alleles of KRAS, BRAF and PIK3CA conferred 
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resistance to combinatorial treatment (Fig. 6A and Supplementary Fig. S10A), 
due to sustained ERK and/or AKT activation (Fig. 6B and Supplementary Fig. 
S10B).  
 
 4. Discussion 
 
Human cancer cell lines represent a tool extensively exploited in the last half  
century to study the biology of different tumor types as well as for extensive 
drug screening efforts. Exceptional efforts such as the generation of the 
Cancer Cell Line Encyclopedia (7) have been pivotal for unveiling novel 
genomic correlates of drug sensitivities in 36 tumor types, thus coupling cell 
line genomic annotation to individual pharmacological profiles.  
 
We have previously described a bowel cancer cell-line collection including 
151 established cell lines (53). This platform can recapitulate the majority of 
CRC molecular and transcriptional subtypes previously defined in patients. 
Genomic analysis has allowed the identification of novel outliers in response 
to selected targeted agents. Yet, infrequent molecular subtypes or tumors 
carrying rare genetic lesions may be under-represented or completely absent 
in the above-mentioned CRC cell lines collection. For instance, while ERRB2 
amplified cell line models have been widely employed for breast cancer 
studies, none of the models in the 151-CRC cell collection were found to carry 
this alteration.  In this work, we provide an accurate characterization of two 
novel cancer cell lines of colorectal origin bearing ERRB2 amplification – 
which could be used in the future to further dissect the role of ERBB2 
oncogenic signaling in the context of gut pathophysiology. 
 
Cell lines may have intrinsic limitations that hamper representation of the 
whole tumor disease in the patient. Common immortalized cell lines have 
been adapted to growing on plastic for decades and this may have caused 
genetic drifts and the acquisition of phenotypic features different from original 
cancers in patients. It is now evident that CRC is indeed a heterogeneous 
disease whose development and progression rely on continuous evolution of 
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multiple clones under environmental and pharmacological pressure (54).For 
this reason, precision medicine, which is based on the design of personalized 
treatments, requires a repertoire of preclinical models that mirror the in vivo 
tumor more closely than conventional cancer cell lines. Derivation of long-
term culture directly from tumor samples has proven to be difficult and 
inefficient, at least in CRC, not only because of contaminations but also due to 
failure to adhere to the culture dish or loss of proliferative capacity after a few 
passages (55). Establishment of short-term tumor cell culture has proven to 
be successful (56), but long-term experiments as well as gene editing by 
lentiviral transduction for experimental needs might not be feasible.  
 
Generation of PDX models has contributed to the identification and validation 
of biomarkers of response and resistance to current anticancer therapies (17). 
However, they present some important shortcomings such as long time for 
establishment and expansion, cumbersome manipulation and cost-ineffective 
experiments, especially if set on a large scale. 
 
Here we present a complementary approach based on PDX-derived cell lines. 
We have established 29 cell lines from PDXs originally derived from samples 
of primary or metastatic CRC tissue. Initially, to assess whether passage from 
3D/in vivo to 2D/in vitro growing condition did not select for genomic 
alterations that may compromise the biology of the tumor, we performed 
genetic and transcriptomic analyses to compare samples. Whole exome 
sequencing confirmed preservation of the PDX main genetic features in 2D-
derived cell lines, which remained stable during extended passaging. 
Importantly, in contrast to conventional cell lines, we could take advantage of 
the matched normal (germline) DNA to identify somatic tumor alterations 
versus germline variants. High concordance in genetic variation was evident 
between the two platforms when considering cancer-related genes, although 
we identified a variable range of private mutation variation in each PDX-XL 
pair. This variation could either reflect the enrichment/depletion of a sub-
clonal population, or the acquisition of additional mutations during derivation 
or propagation of the XL-cells with respect to the matched xenopatient.  
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In line with these observations, gene expression profiles of matched XLs and 
PDX models were highly correlated, confirming the stability of the tumor 
models upon propagation in vitro. Likewise, the molecular classification of cell 
lines based on transcriptional traits did reproduce the occurrence observed in 
the original tumor, and conserved its distinct associations with genetic, 
molecular and pharmacological associations. Indeed, despite the small size of 
our dataset, we could confirm the association between CRIS-C assignment 
and higher probability of response to anti-EGFR treatment, as well as the 
association between CRIS-A and MSI status.  
Of note, comparing the classification of CMS and CRIS in the context of cell 
models we unveiled correspondence in classification of CMS4 and CRIS-D, 
likely emerging due to absence of stromal cells in the cancer cells profiles and 
similarities in intrinsic traits, such as the LGR5 stem-like signature detected in 
both subtypes (29,57).  
 
We next assessed whether these new preclinical models could represent a 
reliable tool for biomarker validation and pharmacological screening. The 
identification of genomic players that may confer sensitivities or resistance to 
selected therapies is of paramount importance for the design of effective 
therapeutic strategies. As a proof of concept, we have shown two 
independent examples in which the results observed with the XLs highly 
mirrored what was previously observed in PDXs. We focused our attention on 
anti-HER therapies, which are approved or investigational agents for patients 
with RAS wild-type and HER2-overexpressing CRC tumors. When we 
challenged XL-cells with the anti-EGFR monoclonal antibody cetuximab, we 
observed a distribution of responses that closely correlated with genetic and 
non-genetic biomarkers of resistance identified in the corresponding PDXs. 
 
As a paradigmatic example, we have identified in our cohort two XLs 
harboring HER2 receptor overexpression due to ERBB2 gene amplification. 
When these cells where challenged with a rational combination of HER 
inhibitors, we observed that their proliferation was severely impaired, as 
previously seen with the matched PDXs treated with the same drugs. This 
further confirms the XL platform as a valuable tool for genotype-drug 
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correlation studies. Moreover, we have validated molecular determinants of 
resistance to dual HER2 blockade in CRC, as emerged from the HERACLES 
trial (52), suggesting that combinatorial treatment with other targeting agents 
might be beneficial for HER2+ patients (51).  
 
In summary, we have established a compendium of 29 XLs that substantially 
recapitulate the genomic features of matched PDXs, with the great advantage 
of providing ease of handling and amenability for high-throughput compound 
screening. This may significantly accelerate the translation of drug-response 
information from in vitro testing to clinical practice. 
 
Another notable advantage provided by this approach is the possibility of 
generating cell lines with genotypes that are either missing o rare in common 
commercial repositories (i.e. HER2 amplified or NRAS Q61 mutated cell 
lines), as well as increasing the number of MSS CRC cell lines, which are 
typically underrepresented in existing cell line collections (34,53). It derives 
that the more XLs we manage to establish, the more we will have the chance 
to understand and model the molecular underpinnings of CRC heterogeneity. 
In conclusion, we present a novel preclinical platform that – owing to its 
reliability, large-scale use and proximity to original patient tumors – could offer 
easier and more rapid access to the dissection of genetic and patient-
selective therapeutic vulnerabilities, thus leading to the design of novel 
effective treatment strategies.  
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Figure Legends 
 
Figure 1. Exome Sequencing analysis of XLs matches the profile of the 
corresponding PDX of origin. 
A. Site of origin of PDX samples used to generate XLs. 
B. Relative distribution of microsatellite status in XL-cells.  
C. Number of MSI events in the 29 PDX-XL pairs, stratified by the length 
of the repeat units identified by exome analysis. 
D. Mutational load (number of mutations per Mb) in the 29 PDX-XL pairs, 
as calculated by exome analysis. 
E. The counts of non-synonymous mutations (blue bar) and INDELs (red 
bar) in the 29 PDX-XL pairs, as calculated by exome analysis. 
F. Mutational spectra in the 29 PDX-XL pairs, as relative proportion of the 
six different possible base-pair substitutions (nucleotide transitions and 
trasversions). 
Microsatellite stable (MSS) and unstable (MSI-H) cases are highlighted in light 
blue and red, respectively. 
 
Figure 2. Comparison of copy-number variation unveils gain or loss of 
selected genome segments in PDX-XL matched models. 
A. Heat map comparing copy-number aberration between matched PDX and 
XL models in log2 scale, as assessed by WES. Red colors indicate gains, 
while blue colors indicate losses. The band on the left represents 
chromosomes 1-22. 
B. Plot of frequency of gains and losses for each position per group (PDX and 
XL) along the genome, as assessed by WES. Each horizontal dotted line 
represents chromosomal boundaries. 
C. Heat map comparing copy-number between matched PDX and XL models 
in log2 scale for the indicated genes.  
 
Figure 3. Genomic landscape of deregulated signaling pathways in PDX-
XL pairs. 
A. Landscape of the gene alterations found in the PDX-XL pairs; missense 
mutations (gray boxes), nonsense mutations (black boxes), insertion (yellow 
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boxes) and deletion (violet boxes) as well as co-occurrence of multiple 
alterations (green boxes) are displayed. Orange squared boxes indicate gene 
amplification, while blue squared boxes indicate gene downregulation. Genes 
are grouped according to signaling pathways; cases are grouped according to 
transcriptional CRIS classification of XLs (as assessed in (28)). Primary tumor 
site (right and left) for each cell line are also reported. MSI-H cases are also 
shown.  
B. Percentage of gene alterations in PDX-XL pairs (gray bars) are compared 
to percentage of cases reported in TCGA CRC cases (red bars). 
C.Caleydo view of correspondences between the CRIS vs CMS class 
assignments of XLs.  
 
Figure 4. Cetuximab screening in XLs. Bar graph representing the effect of 
cetuximab treatment normalized on control untreated cells for the XLs. 
Viability was assessed by measuring ATP content after 6 days of treatment 
with cetuximab at the clinically relevant dose of 10 ug/ml. Data represent the 
average of value obtained from at least three independent experiments, error 
bars represent SD. Based on their response to cetuximab, cell lines were 
subdivided in three different groups: resistant (first tertile, range 66-100%), 
intermediate (second tertile, range 65-34%) and sensitive (third tertile, range 
33-1%). MSI-H cells are highlighted in light yellow and for each cell line its 
CRIS classification is reported. 
 
Figure 5. Identification of overexpressed receptor tyrosine kinases 
(RTKs) in CRC XLs and effects of HER blockade in ErBB2 amplified cell 
models.  
A. Heatmap showing the relative expression (log2 ratio FPKM) of receptor 
tyrosine kinases (RTKs) as identified by RNA-seq analysis of 29 XLs. RTKs 
listed here (n=32) represent the only members of this class of protein passing 
the filtration process during RNA-seq analysis. KRAS, BRAF and NRAS 
mutated cases are also indicated.  
B. Scatter plot displaying the correlation between absolute ERBB2 
expression (FPKM, x-axis) and relative ERBB2 copy-number variation (CNV, 
log2ratio) in the 29 XLs, as assessed by RNA-seq and WES sequencing 
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analyses, respectively. ERBB2-overexpressing and amplified xeno-cell lines 
(CRC0080-XL and CRC01086) are indicated.  
C. Short-term viability assay showing the effects of single dose of 
trastuzumab (TMAB, 25 g/m), lapatinib (LAP, 120 nM), and combination of 
lapatinib and trastuzumab (LAP+TMAB) on HER2-amplified CRC0186-XL (left 
panel) and CRC080-XL (right panel). Viability was assessed by measuring 
ATP content after 6 days of treatment. Data represent the values obtained 
from at least three independent experiments in triplicate, normalized on 
control DMSO-treated cells; error bars indicate SD (lapatinib vs 
lapatinib+trastuzumab in CRC0186: ***, P = 0.001; lapatinib vs 
lapatinib+trastuzumab: **, P = 0.0036 in CRC080; unpaired Student’s t test. 
IC50 values were calculated from dose inhibition curves using GraphPad 
Prism software.  
D. Activation status/phosphorylation of HER2 receptor and downstream 
pathway in dose-response experiments in CRC0186-XL (left panel) and 
CRC080-XL (right panel). Cells were treated with the indicated concentrations 
of trastuzumab (TMAB), lapatinib (Lap), or the combination of both drugs for 4 
hours. Cell extracts were immunoblotted with the indicated antibodies. HSP90 
was used as loading control. 
E. In vivo tumor growth curves of CRC0186 PDX (n=6) and CRC080 PDX 
(n=6) treated with the indicated modalities. Data represent the mean of tumor 
volume at each time point; error bars indicate S.E.M. (lapatinib vs 
lapatinib+trastuzumab: ***, P < 0.001 by two-way Anova Test. Response 
curves for both models were previously reported in (51) and are reshown here 
for comparative purposes. 
 
Figure 6. Constitutive expression of mutant RAS/BRAF/PIK3CA 
mediates resistance to lapatinib+trastuzumab combinatorial treatment in 
ErBB2 amplified cells. 
A. Long term viability assay showing the effect of different indicated doses 
of lapatinib in absence or in presence of doses of 25 g/ml of trastuzumab on 
HER2-amplified CRC0186-XL transduced with lentiviral vector overexpressing 
BRAF V600E, KRAS G13D or PIK3CA H1047R mutants. Cells transduced 
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with empty lentiviral vector were used as control (CTRL). Cell viability was 
measured by crystal violet staining after 15 days of treatment. Representative 
wells were photographed and reported. 
B.  Activation status/phosphorylation of HER2 receptor and downstream 
pathway in dose-response experiments in CRC0186-XL transduced with 
lentiviral vector overexpressing the indicated alleles. Cells transduced with 
empty lentiviral vector were used as control. Cells were treated with the 
combination of 500 nM of lapatinib and 10 g/ml of trastuzumab (L+T) for 4 
hours. Cell extracts were immunoblotted with the indicated antibodies. 
Vinculin was used as loading control. 
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